Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular Lymphoma
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 41
- Registration Number
- NCT02472756
- Locations
- 🇷🇸
Institute of Hematology, Belgrade, Serbia
🇷🇸Clinical Center Kragujevac, Kragujevac, Serbia
🇷🇸Clinic of Haematology Cc Nis, NIS, Serbia
A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RG1662 in Healthy Subjects
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT02470832
Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer
- Conditions
- Cervical Cancer
- Interventions
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2019-06-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 152
- Registration Number
- NCT02467907
- Locations
- 🇬🇷
IASO, Athens, Greece
🇨🇴Oncólogos de Occidente, Pereira, Colombia
🇲🇽Instituto Nacional de Cancerologia; Oncology, Distrito Federal, Mexico
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 55
- Registration Number
- NCT02465606
- Locations
- 🇺🇸
Allergy and Asthma Relief Experts, Granada Hills, California, United States
🇺🇸T. Joseph Raoof Md, Inc., Encino, California, United States
🇺🇸Allergy and Asthma Associates of Southern California - CRN, Mission Viejo, California, United States
Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia
- Conditions
- Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Cancer
- Interventions
- Other: No intervention
- First Posted Date
- 2015-06-03
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 22
- Registration Number
- NCT02461316
Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1
- First Posted Date
- 2015-06-03
- Last Posted Date
- 2015-09-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 99
- Registration Number
- NCT02461290
A Study of Atezolizumab in Advanced Solid Tumors
- Conditions
- Tumors
- Interventions
- First Posted Date
- 2015-06-01
- Last Posted Date
- 2021-06-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 474
- Registration Number
- NCT02458638
- Locations
- 🇮🇪
St Vincent'S Uni Hospital; Medical Oncology, Dublin, Ireland
🇳🇴Oslo Universitetssykehus HF; Radiumhospitalet, Oslo, Norway
🇨🇭Freiburger Spital; Onkologie, Fribourg, Switzerland
Disease Characteristics, Treatment Patterns and Clinical Outcomes in Patients With Newly Diagnosed Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) in China
- Conditions
- Non-Small Cell Lung Cancer, Lung Cancer, Cancer
- Interventions
- Other: No intervention
- First Posted Date
- 2015-06-01
- Last Posted Date
- 2018-11-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1378
- Registration Number
- NCT02458651
- Locations
- 🇨🇳
Sichuan Provincial Cancer Hospital, Chengdu, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences., Beijing, China
🇨🇳the First Hospital of Jilin University, Changchun, China
A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2019-08-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 66
- Registration Number
- NCT02453087
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸New York University Cancer Cen, New York, New York, United States
🇺🇸Medical Center of Aurora; Rocky Mountain Cancer Centers, Aurora, Colorado, United States
A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 212
- Registration Number
- NCT02453256
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
🇫🇷Hopital Claude Huriez; Internal Medicine, Lille, France
🇺🇸Joint & Muscle Research Institute, Charlotte, North Carolina, United States